NEO-Match nanomechanical testing of pancreatic tumor samples
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)
NA · ARTIDIS AG · NCT07542041
This will test whether the NEO-Match® nanomechanical test on biopsy tissue can help predict response to pre-surgery treatment and detect cancer in people with suspected pancreatic tumors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | ARTIDIS AG (industry) |
| Locations | 1 site (Tampa, Florida) |
| Trial ID | NCT07542041 on ClinicalTrials.gov |
What this trial studies
This prospective, single-arm study at Moffitt Cancer Center collects one extra biopsy sample during routine pancreatic biopsy or surgery for analysis with the ARTIDIS ART-1 atomic force microscopy device. The ART-1 measures nanomechanical properties of fresh tissue to generate a NEO-Match® score, which will be compared with standard histopathology, imaging findings, and clinical outcomes including response to neoadjuvant therapy. Participation is integrated into standard clinical workflow and does not alter or delay care. Researchers aim to see if nanomechanical profiling can improve diagnostic accuracy and predict treatment response in pancreatic ductal adenocarcinoma.
Who should consider this trial
Good fit: Adults (age ≥18) referred for fine-needle biopsy of a suspicious pancreatic lesion who can provide informed consent are the intended participants.
Not a fit: Patients not undergoing biopsy, with lesions inaccessible for sampling, or requiring immediate palliative care are unlikely to benefit from this testing.
Why it matters
Potential benefit: If successful, the test could give clinicians earlier and more accurate information to guide decisions about pre-surgical therapy and other treatments.
How similar studies have performed: AFM-based nanomechanical profiling has shown promise in pilot studies for distinguishing malignant from benign tissue, but its predictive use for neoadjuvant response in pancreatic cancer is still largely unproven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Ability to understand and willingness to sign a written informed consent form * Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy Exclusion Criteria: * Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study
Where this trial is running
Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida, United States (RECRUITING)
Study contacts
- Study coordinator: Julia Ortega, DMSc, MHS, PA
- Email: julia.ortega@artidis.com
- Phone: 2404980176
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Pancreatic Lesions Located at the Body or the Tail, Atomic Force Microscopy, Neoadjuvant Therapy, Nanomechanical Profiling, NEO-Match